|Description||Human sDLL-1 comprises the extracellular signaling domain of DLL1, a member of a structurally-related family of single-pass type I trans-membrane proteins that serve as ligands for Notch receptors. It is expressed in the heart and pancreas, and to a lesser extent in various other tissues. DLL-1 functions to specifically activate the Notch-1 and Notch-2 receptors. The Notch signaling pathway regulates endothelial-cell differentiation, proliferation and apoptosis, and is essential for the development, maintenance and remodeling of the vascular system. DLL-1 suppresses differentiation of hematopoietic progenitor cells into the B-cell lineage while promoting differentiation to T-cell and NK cell precursors. Recombinant human sDLL-1 is a 57.0-60.0 kDa glycoprotein containing 522 amino-acid residues.|
|BiologicalActivity||Determined by the dose dependent growth suppression of the human acute monocytic leukemia cell line, THP-1. sDLL-1 inhibits the proliferation in THP-1 cells using a concentration of 3.0-5.0 μg/ml.|
|Authenticity||Verified by N-terminal and Mass Spectrometry analyses (when applicable).|
|Endotoxin||Endotoxin level is <0.1 ng/ µg of protein (<1EU/ µg).|
|Protein Content||Verified by UV Spectroscopy and/or SDS-PAGE gel.|
|Precautions||Recombinant Human sDLL-1 is for research use only and not for use in diagnostic or therapeutic procedures.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have any additional inquiries please email technical services at email@example.com.